Idamycin (Idarubicin) Drug Information: Description, User Reviews, Drug Side Effects, Interactions

Pill Identifier Search

February 9, 2012

Idamycin

Leukemia »

Leukemia facts

Leukemia is a cancer of the blood cells.
While the exact cause(s) of leukemia is not known, risk factors have been identified.
Leukemias are grouped by how quickly the disease develops (acute or chronic) as well as by the type of blood cell that is affected (lymphocytes or myelocytes). The four main types of leukemia include acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelocytic leukemia (AML), and chronic myelocytic leukemia (CML).
People with leukemia are at significantly increased risk for developing infections, anemia, and bleeding. Other symptoms and signs include easy bruising, weight loss, night sweats, and unexplained fevers.
The diagnosis of leukemia is supported by findings of the medical history and examination, and examining blood and bone marrow samples under a microscope.
Tre...

Read the Leukemia article »

« Previous
1
2
3
4
5
6
7
8
9
10
next »

Idamycin

font size

Idamycin®
(idarubicin hydrochloride) for Injection, USP

WARNINGS

IDAMYCIN (idarubicin hydrochloride for injection, USP) should be given slowly into a freely flowing intravenous infusion. It must never be given intramuscularly or subcutaneously. Severe local tissue necrosis can occur if there is extravasation during administration.
As is the case with other anthracyclines the use of IDAMYCIN (idarubicin) can cause myocardial toxicity leading to congestive heart failure. Cardiac toxicity is more common in patients who have received prior anthracyclines or who have preexisting cardiac disease.
As is usual with antileukemic agents, severe myelosuppression occurs when IDAMYCIN (idarubicin) is used at effective therapeutic doses.
It is recommended that IDAMYCIN (idarubicin) be administered only under the supervision of a physician who is experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.
Dosage should be reduced in patients with impaired hepatic or renal function. (See DOSAGE AND ADMINISTRATION.)

DRUG DESCRIPTION

IDAMYCIN® (idarubicin hydrochloride for injection, USP) is a sterile, semi-synthetic antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride is 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride, (7S-cis). The structural formula is as follows:

Idamycin® (idarubicin hydrochloride) Structural Formula Illustration

C₂₆H₂₇NO₉•Hcl M.W 533.96

IDAMYCIN (idarubicin) , a sterile lyophilized powder for reconstitution and intravenous administration, is available in a 20 mg single use only vial.

Each 20 mg vial contains 20 mg Idarubicin Hydrochloride, USP and 200 mg of Lactose NF (hydrous) as an orange-red, lyophilized powder.

What are the precautions when taking idarubicin (Idamycin)?

Before using idarubicin, tell your doctor or pharmacist if you are allergic to it; or to other anthracyclines (e.g., doxorubicin); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: blood/bleeding disorders (e.g., anemia, low blood cell counts), gout, heart disease (e.g., congestive heart failure, irregular heartbeat), kidney disease, liver disease, radiation treatment (especially to chest area).

Do not have immunizations/vaccinations without the consent of your doctor, and avoid contact with people who have recently received oral polio vaccine or flu...

Read All Potential Precautions of Idamycin »

Last reviewed on RxList: 10/9/2008
This monograph has been modified to include the generic and brand name in many instances.